CASG 209

CASG 209

• 批准号: 7603481
• 负责人: ABHIJIT Prakash LIMAYE
• 金额: $ 0.04万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603481
• 关键词: Affect; BK Virus; Cidofovir; Computer Retrieval of Information on Scientific Projects Database; Cytomegalovirus; Disease; Dose; Double-Blind Method; Effectiveness; Funding; Grant; Institution; Kidney Diseases; Kidney Transplantation; Marketing; Newly Diagnosed; Patients; Pharmacia brand of cidofovir; Placebo Control; Randomized; Research; Research Personnel; Resources; Safety; Source; Transplant Recipients; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized, double-blind, placebo-controlled, sequential dose escalation study to evaluate the safety, tolerability, maximum tolerance dose, physical affects and preliminary effectiveness of cidofovir in kidney transplant recipients with newly diagnosed BK virus-induced nephropathy (kidney disorder). Cidofovir VISTIDE is a marketed product for cytomegalovirus disease in HIV-infected patients.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项随机、双盲、安慰剂对照、序贯剂量递增研究，旨在评估西多福韦在肾移植受者中的安全性、耐受性、最大耐受剂量、身体影响和初步有效性，这些受者患有新诊断的BK病毒诱导的肾病（肾脏疾病）。西多福韦VISTIDE是一种上市产品，用于HIV感染患者的巨细胞病毒疾病。